Comparing two EGFR antibody treatments for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new antibody drug against a standard one, both combined with chemotherapy, for advanced colorectal cancer that has not spread before. It aims to see which is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced colorectal cancer that has not been treated before.
- Your tumor must have normal RAS/BRAF genes and be MSS/pMMR type.
- You should be in good general health (able to do daily activities).
- You must have at least one measurable tumor spot.
- You must not have had certain prior treatments like EGFR antibodies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted drug (anti-EGFR) to chemotherapy helps people with right-sided advanced colorectal cancer whose tumors have certain gene markers. It may offer a more personalized treatment option.
This trial tests two different drug combinations for people with advanced bowel cancer that has a specific genetic change (RAS mutation) and has already been treated with one type of chemotherapy. The goal is to see if one combination works better than the other.
This trial tests a new drug called CC-3, which is a type of antibody designed to help your immune system attack colorectal cancer cells. It is for people whose cancer has spread and who have already tried several standard treatments.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial compares two standard chemotherapy combinations for people whose colorectal cancer has spread and cannot be removed with surgery. Depending on certain genetic markers, participants also receive either bevacizumab or cetuximab to help the treatment work better.
This study tests a new combination of drugs (Envafolimab, Cetuxima-β, and mFOLFOX6) for people with a specific type of advanced colorectal cancer that has not been treated yet. It aims to see if this combination is safe and more effective than standard treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.